Regular purchase channels for Sotorasib

Sotorasib is a revolutionary anti-cancer drug specifically designed to treat KRAS G12C mutated non-small cell lung cancer (NSCLC). KRAS G12C is a mutated form of a cancer-related gene, especially common in NSCLC. By precisely targeting this specific genetic mutation, sotoracib provides a new treatment option for patients with this type of lung cancer.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

Its mechanism of action is mainly to combat KRAS G12C mutant, which drives the abnormal growth and spread of cancer cells. Sotoracib specifically binds to the KRAS G12C protein, interferes with its active site, and blocks abnormal signaling pathways, thereby effectively inhibiting the proliferation and spread of cancer cells.

Clinical trials of sotoraxib have shown some encouraging results. Sotoraxib demonstrated significant anti-tumor activity in patients with KRAS G12C mutant non-small cell lung cancer who had previously had limited response to conventional treatments. After patients receive drug treatment, their tumors may shrink or be stabilized, bringing new hope to patients with this specific subtype of lung cancer.